Efficacy of imatinib maintenance after stem cell transplantation for Ph+/BCR::ABL1 positive ALL: long-term outcome of a randomized trial and impact of peritransplant minimal residual disease.
Saved in:
| Title: | Efficacy of imatinib maintenance after stem cell transplantation for Ph+/BCR::ABL1 positive ALL: long-term outcome of a randomized trial and impact of peritransplant minimal residual disease. |
|---|---|
| Authors: | Pfeifer H; Department of Medicine, Hematology/Oncology, Goethe University Frankfurt, Frankfurt, Germany., Bethge W; Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University of Tuebingen Medical Center, Tuebingen, Germany., Schönland S; Department of Hematology/Oncology and Rheumatology, University of Heidelberg, Heidelberg, Germany., Heberling L; Department of Internal Medicine I, Haematology and Oncology, University Hospital Carl Gustav Carus Dresden, Dresden, Germany., Ruhnke L; Department of Internal Medicine I, Haematology and Oncology, University Hospital Carl Gustav Carus Dresden, Dresden, Germany., Stadler M; Department of Hematology, Hemostasis, Oncology, and Cellular Therapy, Hannover Medical School, Hannover, Germany., Beelen D; Department of Haematology and Stem Cell Transplantation, University of Duisburg-Essen, University Medicine Essen, Essen, Germany., Vučinić V; Department of Hematology, Hemostaseology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany., Burmeister T; Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Clinic, Campus Charité-Mitte and Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Berlin, Germany., Stelljes M; Department of Medicine A/Hematology and Oncology, University of Muenster, Muenster, Germany., Faul C; Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University of Tuebingen Medical Center, Tuebingen, Germany., Kiani A; Department of Medicine IV, Klinikum Bayreuth GmbH, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany., Wendelin K; Oncology, Hematology and Bone Marrow Transplantation Unit, Paracelsus Medizinische Privatuniversitat - Nurnberg, Nürnberg, Germany., Schwerdtfeger R; Helios Klinikum Buch, Berlin, Germany., Lange E; Clinic for Hematology, Oncology and Palliative Care and Stem Cell Transplantation, Alexianer Hospital Hochsauerland, Meschede, Germany., Kubuschock B; Department of Internal Medicine II, Augsburg University Medical Center and Bavarian Cancer Research Center (BZKF), Partner Cite Augsburg, Augsburg, Germany., Horst HA; University Hospital Schleswig Holstein, Kiel, Germany., Gramatzki M; Division of Stem Cell Transplantation and Immunotherapy, University of Kiel, Kiel, Germany., Serve H; Department of Medicine, Hematology/Oncology, Goethe University Frankfurt, Frankfurt, Germany.; Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany.; German Cancer Consortium (DKTK), Frankfurt, Germany.; Frankfurt Cancer Institute (FCI, Frankfurt), Frankfurt, Germany., Hoelzer D; Onkologikum Frankfurt, Frankfurt, Germany., Gökbuget N; Department of Medicine, Hematology/Oncology, Goethe University Frankfurt, Frankfurt, Germany., Ottmann OG; Division of Cancer and Genetics, Cardiff University School of Medicine, Cardiff, UK., Lang F; Department of Medicine, Hematology/Oncology, Goethe University Frankfurt, Frankfurt, Germany. |
| Corporate Authors: | GMALL Study Group |
| Source: | Leukemia & lymphoma [Leuk Lymphoma] 2026 Aug 02, pp. 1-9. Date of Electronic Publication: 2026 Aug 02. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
